JP6908964B2 - Ｐｓｍａリガンドコンジュゲートによる併用療法 - Google Patents

Ｐｓｍａリガンドコンジュゲートによる併用療法 Download PDF

Info

Publication number
JP6908964B2
JP6908964B2 JP2013235506A JP2013235506A JP6908964B2 JP 6908964 B2 JP6908964 B2 JP 6908964B2 JP 2013235506 A JP2013235506 A JP 2013235506A JP 2013235506 A JP2013235506 A JP 2013235506A JP 6908964 B2 JP6908964 B2 JP 6908964B2
Authority
JP
Japan
Prior art keywords
psma
cells
antibody
ligand
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2013235506A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015078168A5 (https=
JP2015078168A (ja
Inventor
シー． オルソン，ウィリアム
シー． オルソン，ウィリアム
Original Assignee
ピーエスエムエー ディベロップメント カンパニー，エルエルシー
ピーエスエムエー ディベロップメント カンパニー，エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ピーエスエムエー ディベロップメント カンパニー，エルエルシー, ピーエスエムエー ディベロップメント カンパニー，エルエルシー filed Critical ピーエスエムエー ディベロップメント カンパニー，エルエルシー
Priority to CA3181096A priority Critical patent/CA3181096A1/en
Priority to PCT/US2014/000124 priority patent/WO2015057250A1/en
Priority to ES14734570T priority patent/ES2837927T3/es
Priority to EP14734570.6A priority patent/EP3057614B1/en
Priority to EP20199101.5A priority patent/EP3827844A1/en
Priority to AU2014337391A priority patent/AU2014337391B2/en
Priority to CA2927735A priority patent/CA2927735C/en
Priority to US14/277,367 priority patent/US20150110814A1/en
Publication of JP2015078168A publication Critical patent/JP2015078168A/ja
Publication of JP2015078168A5 publication Critical patent/JP2015078168A5/ja
Priority to JP2019111139A priority patent/JP7716836B2/ja
Priority to AU2020203191A priority patent/AU2020203191B2/en
Application granted granted Critical
Publication of JP6908964B2 publication Critical patent/JP6908964B2/ja
Priority to AU2023200926A priority patent/AU2023200926A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2013235506A 2013-10-18 2013-11-13 Ｐｓｍａリガンドコンジュゲートによる併用療法 Active JP6908964B2 (ja)

Priority Applications (11)

Application Number Priority Date Filing Date Title
US14/277,367 US20150110814A1 (en) 2013-10-18 2014-05-14 Combination therapies with psma ligand conjugates
ES14734570T ES2837927T3 (es) 2013-10-18 2014-05-14 Terapias de combinación con conjugados de ligando de PSMA
EP14734570.6A EP3057614B1 (en) 2013-10-18 2014-05-14 Combination therapies with psma ligand conjugates
EP20199101.5A EP3827844A1 (en) 2013-10-18 2014-05-14 Combination therapies with psma ligand conjugates
AU2014337391A AU2014337391B2 (en) 2013-10-18 2014-05-14 Combination therapies with PSMA ligand conjugates
CA2927735A CA2927735C (en) 2013-10-18 2014-05-14 Combination therapies with psma ligand conjugates
CA3181096A CA3181096A1 (en) 2013-10-18 2014-05-14 Combination therapies with psma ligand conjugates
PCT/US2014/000124 WO2015057250A1 (en) 2013-10-18 2014-05-14 Combination therapies with psma ligand conjugates
JP2019111139A JP7716836B2 (ja) 2013-10-18 2019-06-14 Ｐｓｍａリガンドコンジュゲートによる併用療法
AU2020203191A AU2020203191B2 (en) 2013-10-18 2020-05-15 Combination therapies with psma ligand conjugates
AU2023200926A AU2023200926A1 (en) 2013-10-18 2023-02-17 Combination therapies with psma ligand conjugates

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361893145P 2013-10-18 2013-10-18
US61/893,145 2013-10-18

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019111139A Division JP7716836B2 (ja) 2013-10-18 2019-06-14 Ｐｓｍａリガンドコンジュゲートによる併用療法

Publications (3)

Publication Number Publication Date
JP2015078168A JP2015078168A (ja) 2015-04-23
JP2015078168A5 JP2015078168A5 (https=) 2017-07-20
JP6908964B2 true JP6908964B2 (ja) 2021-07-28

Family

ID=53009949

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2013235506A Active JP6908964B2 (ja) 2013-10-18 2013-11-13 Ｐｓｍａリガンドコンジュゲートによる併用療法
JP2019111139A Active JP7716836B2 (ja) 2013-10-18 2019-06-14 Ｐｓｍａリガンドコンジュゲートによる併用療法
JP2023076905A Pending JP2023135666A (ja) 2013-10-18 2023-05-08 Ｐｓｍａリガンドコンジュゲートによる併用療法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2019111139A Active JP7716836B2 (ja) 2013-10-18 2019-06-14 Ｐｓｍａリガンドコンジュゲートによる併用療法
JP2023076905A Pending JP2023135666A (ja) 2013-10-18 2023-05-08 Ｐｓｍａリガンドコンジュゲートによる併用療法

Country Status (4)

Country Link
EP (2) EP3827844A1 (https=)
JP (3) JP6908964B2 (https=)
AU (3) AU2014337391B2 (https=)
CA (2) CA2927735C (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10806806B2 (en) 2016-06-23 2020-10-20 Cornell University Trifunctional constructs with tunable pharmacokinetics useful in imaging and anti-tumor therapies
GB201614162D0 (en) * 2016-08-18 2016-10-05 Polytherics Ltd Antibodies, uses thereof and conjugates thereof
WO2018204477A1 (en) * 2017-05-02 2018-11-08 Cornell University Methods and reagents for tumor targeting with greater efficacy and less toxicity
WO2019088176A1 (ja) * 2017-10-31 2019-05-09 国立大学法人神戸大学 抗体薬物複合体効果増強剤
EP4344747A3 (en) * 2017-11-30 2024-07-03 LadRx Corporation Albumin-binding prodrugs of auristatin e derivatives
US20200297877A1 (en) 2017-12-13 2020-09-24 Sciencons AS Complex comprising a psma-targeting compound linked to a lead or thorium radionuclide
WO2020077259A1 (en) * 2018-10-11 2020-04-16 Progenics Pharmaceuticals, Inc Combination therapy for treating metastatic prostate cancer
CN119792549A (zh) * 2021-04-23 2025-04-11 天津全和诚生物技术有限公司 缀合物及其制备方法和用途
WO2025125469A1 (en) * 2023-12-13 2025-06-19 Swiss Rockets Ag Combination therapy using psma-targeted radiopharmaceuticals and an inhibitor of pi3k, akt, and/or mtor
CN117778322B (zh) * 2023-12-17 2025-02-07 苏州拓维生物技术有限公司 一种对恩杂鲁胺耐药的细胞系的筛选方法及其应用
WO2025216238A1 (ja) * 2024-04-09 2025-10-16 国立大学法人広島大学 薬物コンジュゲート又はその塩

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5162504A (en) 1988-06-03 1992-11-10 Cytogen Corporation Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients
US5124471A (en) 1990-03-26 1992-06-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Bifunctional dtpa-type ligand
US5756825A (en) 1992-09-08 1998-05-26 Safavy; Ahmad Hydroxamic acid-based bifunctional chelating compounds
US6034065A (en) 1992-12-03 2000-03-07 Arizona Board Of Regents Elucidation and synthesis of antineoplastic tetrapeptide phenethylamides of dolastatin 10
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US5994292A (en) 1995-05-31 1999-11-30 The United States Of America As Represented By The Department Of Health And Human Services Interferon-inducible protein 10 is a potent inhibitor of angiogenesis
US6962981B1 (en) 1996-03-25 2005-11-08 Medarex, Inc. Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
US6136311A (en) 1996-05-06 2000-10-24 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
US6107090A (en) 1996-05-06 2000-08-22 Cornell Research Foundation, Inc. Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains
WO1998036765A1 (en) 1997-02-25 1998-08-27 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear and cyclo-depsipeptides dolastatin 16, dolastatin 17, and dolastatin 18
WO2002098897A2 (en) * 2001-06-01 2002-12-12 Cornell Research Foundation, Inc. Modified antibodies to prostate-specific membrane antigen and uses thereof
JP5355839B2 (ja) 2001-10-23 2013-11-27 ピーエスエムエー デベロプメント カンパニー， エル．エル．シー． Ｐｓｍａ抗体およびタンパク質マルチマー
DK1912677T3 (da) 2005-06-20 2014-01-13 Psma Dev Company L L C PSMA-antistof-lægemiddel-konjugater
EP2097111B1 (en) 2006-11-08 2015-07-15 Molecular Insight Pharmaceuticals, Inc. Heterodimers of glutamic acid
EA020954B1 (ru) 2008-06-16 2015-03-31 Бинд Терапьютикс, Инк. Загруженные лекарственным средством полимерные наночастицы, фармацевтическая композиция и способ лечения рака
EP2326350B1 (en) * 2008-09-08 2013-09-04 Psma Development Company, L.L.C. Compounds for killing psma-expressing, taxane-resistant cancer cells
AU2010260195B2 (en) 2009-06-15 2014-11-20 Molecular Insight Pharmaceuticals, Inc. Process for production of heterodimers of glutamic acid
US20140099257A1 (en) * 2012-10-05 2014-04-10 Cornell University Androgen Suppression, Prostate-Specific Membrane Antigen and the Concept of Conditionally Enhanced Vulnerability

Also Published As

Publication number Publication date
JP2023135666A (ja) 2023-09-28
AU2014337391B2 (en) 2020-06-11
JP2019194209A (ja) 2019-11-07
CA2927735C (en) 2023-02-07
CA3181096A1 (en) 2015-04-23
EP3057614B1 (en) 2020-09-30
AU2014337391A1 (en) 2016-05-05
EP3827844A1 (en) 2021-06-02
JP2015078168A (ja) 2015-04-23
JP7716836B2 (ja) 2025-08-01
AU2020203191B2 (en) 2023-03-09
CA2927735A1 (en) 2015-04-23
AU2023200926A1 (en) 2023-03-23
EP3057614A1 (en) 2016-08-24
AU2020203191A1 (en) 2020-06-04

Similar Documents

Publication Publication Date Title
JP7716836B2 (ja) Ｐｓｍａリガンドコンジュゲートによる併用療法
US20150110814A1 (en) Combination therapies with psma ligand conjugates
US20210023094A1 (en) Psma antibody-drug conjugates
JP2026053616A (ja) 癌の治療のためのクローディン１８．２に対する抗体を含む治療法
ES2559002T3 (es) Anticuerpos contra PSMA
US9242012B2 (en) Methods for killing PSMA-expressing, taxane-resistant cancer cells
JP2019506136A (ja) 新規抗ｅｍｒ２抗体及び使用方法
JP2021523233A (ja) 抗ｐｄ−１抗体と抗組織因子抗体−薬物コンジュゲートとの組み合わせを用いるがんの治療方法
CN116744976A (zh) 用于治疗实体癌的her3放射免疫疗法
US11040223B2 (en) Compositions and methods related to xCT peptides
EP3618869A1 (en) COMPOSITIONS AND METHODS RELATED TO xCT ANTIBODIES
CA3199259A1 (en) Her3 radioimmunotherapy for the treatment of solid cancers
ES2837927T3 (es) Terapias de combinación con conjugados de ligando de PSMA
HK1116697B (en) Psma antibody-drug conjugates
HK1186110A (en) Psma antibody-drug conjugates
HK1159474B (en) Compounds for killing psma-expressing, taxane- resistant cancer cells

Legal Events

Date Code Title Description
A80 Written request to apply exceptions to lack of novelty of invention

Free format text: JAPANESE INTERMEDIATE CODE: A80

Effective date: 20131213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161111

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161111

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170517

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171101

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180131

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180330

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180501

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180606

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180905

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181206

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190214

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190614

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20190614

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190617

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20190710

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20190813

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20190814

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20191004

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20191008

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20200511

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20200603

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20200828

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201127

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201223

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210128

C23 Notice of termination of proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C23

Effective date: 20210421

C03 Trial/appeal decision taken

Free format text: JAPANESE INTERMEDIATE CODE: C03

Effective date: 20210602

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20210602

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210702

R150 Certificate of patent or registration of utility model

Ref document number: 6908964

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250